Finch Therapeutics Group, Inc. Stock Research

Market Summary

USD0.37-0.03

Delayed

-7.50%

FNCH Stock Price

FNCH RSI Chart

FNCH Valuation

Market Cap

17.7M

Price/Earnings (Trailing)

-0.17

Price/Sales (Trailing)

3.73

EV/EBITDA

0.52

Price/Free Cashflow

-0.23

FNCH Price/Sales (Trailing)

FNCH Profitability

EBT Margin

-411.60%

Return on Equity

-88.27%

Return on Assets

-56.76%

Free Cashflow Yield

-436.3%

FNCH Fundamentals

FNCH Revenue

Revenue Y/Y

-98.78%

Revenue Q/Q

-61.77%

FNCH Earnings

Earnings (TTM)

-106.7M

Earnings Y/Y

-305.53%

Earnings Q/Q

-77.85%

Price Action

52 Week Range

0.305.79

(Low)(High)

Last 7 days

-5.6%

Last 30 days

-6.5%

Last 90 days

2.8%

Trailing 12 Months

-92.9%

FNCH Financial Health

Current Ratio

6.56

Debt/Equity

0.12

Debt/Cashflow

-4.96

FNCH Investor Care

Shares Dilution (1Y)

0.80%

Diluted EPS (TTM)

-2.26

Financials for Finch Therapeutics Group

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	NaN%				18,532,000	19,533,000
Operating Expenses	21.9%	108,562,000	89,068,000	85,924,000	78,517,000	73,588,000
S&GA Expenses	13.6%	32,217,000	28,372,000	26,090,000	21,238,000	22,545,000
R&D Expenses	-6.2%	56,115,000	59,793,000	59,834,000	57,279,000	51,043,000
EBITDA	-40.6%	-101,507,000	-72,190,000	-65,475,000	-55,851,000	-
EBITDA Margin	-10.3%	-3.90	-3.53	-3.01	-	-
Earnings Before Taxes	-39.9%	-106,693,000	-76,277,000	-68,746,000	-58,160,000	-52,196,000
EBT Margin	-11.0%	-4.12	-3.71	-3.14	-	-
Interest Expenses	431.2%	409,000	77,000	8,000	9,000	10,000
Net Income	-39.9%	-106,693,000	-76,277,000	-68,746,000	-58,160,000	-52,196,000
Net Income Margin	-11.0%	-4.12	-3.71	-3.14	-	-
Free Cahsflow	-2.7%	-77,207,333	-75,177,000	-85,639,666	-85,774,333	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-17.7%	188	228	205	225	233
Current Assets	-18.0%	91.00	111	123	143	156
Cash Equivalents	-18.5%	85.00	105	107	133	149
Net PPE	-6.3%	17.00	18.00	19.00	20.00	20.00
Goodwill	-100.0%	-	18.00	18.00	18.00	18.00
Liabilities	-3.0%	67.00	69.00	25.00	23.00	13.00
Current Liabilities	-9.1%	14.00	15.00	17.00	15.00	9.00
Long Term Debt	0%	15.00	15.00	-	-	-
LT Debt, Non Current	0.1%	15.00	15.00	-	-	-
Shareholder's Equity	-24.0%	121	159	180	202	220
Retained Earnings	-19.4%	-248	-208	-185	-160	-141
Additional Paid-In Capital	0.6%	369	367	365	363	362
Accumulated Depreciation	20.3%	8.00	7.00	6.00	4.00	4.00
Shares Outstanding	0.3%	48.00	48.00	48.00	48.00	47.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-6.8%	-74.37	-69.62	-77.56	-67.13	-63.63
Share Based Compensation	8.5%	7.00	7.00	6.00	4.00	6.00
Cashflow From Investing	33.0%	-4.13	-6.17	-8.01	-15.92	-16.07
Cashflow From Financing	0.0%	15.00	15.00	2.00	119	119
Buy Backs	-	0.00	-	-	-	-

Risks for FNCH

What is the probability of a big loss on FNCH?

99.1%

Probability that Finch Therapeutics Group stock will be more than 20% underwater in next one year

95.3%

Probability that Finch Therapeutics Group stock will be more than 30% underwater in next one year.

93.4%

Probability that Finch Therapeutics Group stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FNCH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Finch Therapeutics Group was unfortunately bought at previous high price.

Drawdowns

Returns for FNCH

Cumulative Returns on FNCH

Which funds bought or sold FNCH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-712	288	-%
2023-02-15	Steward Partners Investment Advisory, LLC	unchanged	-	-2,920	1,080	-%
2023-02-15	Virtu Financial LLC	sold off	-100	-25,000	-	-%
2023-02-14	MSD Partners, L.P.	reduced	-60.53	-575,369	73,631	0.01%
2023-02-14	ROYAL BANK OF CANADA	sold off	-100	-	-	-%
2023-02-14	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	155	-28,152	78,848	-%
2023-02-14	MILLENNIUM MANAGEMENT LLC	reduced	-38.7	-166,000	36,000	-%
2023-02-14	SCS Capital Management LLC	sold off	-100	-64,000	-	-%
2023-02-14	Oasis Management Co Ltd.	unchanged	-	-268,000	108,000	0.02%
2023-02-14	Laurion Capital Management LP	unchanged	-	-69,160	27,840	-%

Latest Funds Activity

Are funds buying FNCH calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own FNCH

No. of Funds

Finch Therapeutics Group News

Schedule 13G FIlings of Finch Therapeutics Group

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2022	walton thomas layton	0%	0	SC 13G
Feb 14, 2022	ugwumba chidozie	7.37%	3,500,000	SC 13G

FNCH Fair Value

Recent SEC filings of Finch Therapeutics Group

View All Filings

Date Filed	Form Type	Document
Mar 23, 2023	S-8	Employee Benefits Plan
Mar 23, 2023	8-K	Current Report
Mar 23, 2023	10-K	Annual Report
Feb 23, 2023	4	Insider Trading
Jan 26, 2023	8-K	Current Report
Jan 24, 2023	8-K	Current Report
Jan 06, 2023	8-K	Current Report

Latest Insider Trading transactions for FNCH

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-02-21	Blaustein Marc	sold	-1,755	0.38	-4,619	chief operating officer
2022-10-21	Vittiglio Joseph	sold	-5,054	1.39	-3,636	chief business & legal officer
2022-10-21	Blaustein Marc	sold	-5,054	1.39	-3,636	chief operating officer
2022-06-13	Vittiglio Joseph	acquired	-	-	35,000	chief business & legal officer
2022-06-13	Blaustein Marc	acquired	-	-	35,000	chief operating officer
2021-12-20	Haft Nicholas	bought	649,993	10.18	63,850	-
2021-03-23	SMISEK JEFFERY A	acquired	-	-	1,606,310	-
2021-03-23	SMISEK JEFFERY A	bought	1,500,000	17.00	88,235	-
2021-03-23	FERRANTE DOMENIC J	acquired	-	-	533,254	-
2021-03-23	FERRANTE DOMENIC J	bought	1,750,000	17.00	102,941	-

About Finch Therapeutics Group

Mark Smith

www.finchtherapeutics.com

190

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

FNCH Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
REVENUE:
Total revenue	$ 861	$ 18,532
OPERATING EXPENSES:
Research and development	(57,893)	(57,279)
General and administrative	(38,088)	(21,238)
Impairment of goodwill	(18,057)	0
Restructuring expense	(2,416)	0
Total operating expenses	(116,454)	(78,517)
Net loss from operations	(115,593)	(59,985)
OTHER INCOME (EXPENSE), NET:
Gain on extinguishment of PPP Loan	0	1,827
Interest income, net	252	22
(Loss) gain on disposal of fixed assets, net	(7)	28
Other income (expense), net	702	(52)
Total other income, net	947	1,825
Loss before income taxes	(114,646)	(58,160)
Income tax provision	0	0
Net loss	(114,646)	(58,160)
Net loss attributable to common stockholders, diluted	$ (114,646)	$ (58,160)
Net loss per share attributable to common stockholders, basic	$ (2.40)	$ (1.48)
Net loss per share attributable to common stockholders, diluted	$ (2.40)	$ (1.48)
Weighted Average Number of Shares Outstanding, Basic	47,691,632	39,202,086
Weighted Average Number of Shares Outstanding, Diluted	47,691,632	39,202,086
Collaboration Revenue
REVENUE:
Total revenue	$ 861	$ 18,532

FNCH Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 71,038	$ 133,481
Accounts receivable	144	494
Prepaid expenses and other current assets	3,369	8,576
Total current assets	74,551	142,551
Property and equipment, net	15,936	19,635
Operating right-of-use assets	32,752	5,053
In-process research and development	32,900	32,900
Goodwill	0	18,057
Restricted cash, non-current	2,568	2,268
Other assets	4,232	4,905
TOTAL ASSETS	162,939	225,369
CURRENT LIABILITIES:
Accounts payable	1,097	3,737
Accrued expenses and other current liabilities	10,161	9,925
Operating lease liabilities, current	3,431	1,128
Total current liabilities	14,689	14,790
Deferred tax liability	3,461	3,461
Loan payable, non-current	14,653	0
Operating lease liabilities, non-current	34,255	4,887
Other liabilities	170	7
Total liabilities	67,228	23,145
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 48,053,596 and 47,512,182 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively	48	47
Additional paid-in capital	371,304	363,172
Accumulated deficit	(275,641)	(160,995)
Total stockholders' equity	95,711	202,224
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	$ 162,939	$ 225,369